North America Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User

List of Tables

The North America glioma treatment market is expected to grow from US$ 2,179.88 million in 2022 to US$ 4,377.38 million by 2030. It is estimated to grow at a CAGR of 9.1% from 2022 to 2030.

Initiatives by Regional and State Governments to Provide Patients Access to Treatment Fuels North America Glioma Treatment Market

In December 2021, the Patient Access Network (PAN) Foundation and the American Brain Tumor Association announced a new partnership to support persons with glioblastoma by offering financial assistance for services worth up to US$ 1,600 per year for patients. Moreover, leading companies in the North America glioma treatment market focus on launching new products and developing existing ones. In December 2020, CNS Pharmaceuticals, Inc. announced the authorization of the use of berubicin by the Food and Medication Administration to treat patients with glioblastoma multiforme. In addition, the Food and Medication Administration designated LP-184 by Lantern Pharma Inc. as an orphan medication in August 2021 for treating glioblastoma multiforme and other malignant gliomas. A webinar on glioblastoma multiforme (GBM) and the potential of Lantern Pharma\'s LP-184 for treating GBM and other types of brain cancer was also held in May 2020. Thus, efforts made by regional and state governments to provide patients with access to novel treatments accelerate the North America glioma treatment market growth.

North America Glioma Treatment Market Overview

The North America glioma treatment market in North America is segmented into the US, Canada, and Mexico; the US holds the largest share of the market in this region. The market growth is mainly attributed to the increasing brain tumor cases, rapid technological innovations, and developing healthcare infrastructure. According to a report published by the National Brain Tumor Society in 2023, glioblastoma is one of the deadliest, most complex, and treatment-resistant forms of cancer. Over 14,490 Americans are projected to receive a GBM diagnosis in 2023, accounting for ~50.1% of all primary malignant brain tumors. Prominent players in the North American market are focusing on various growth strategies such as mergers, acquisitions, partnerships, and new product launches to expand their geographic presence and enhance their product offerings. For instance, Elekta, a Sweden-based company, collaborated with GE Healthcare to bring innovations in the field of radiation oncology. Through this collaboration, hospitals would be provided with a wide range of treatments for cancer patients requiring radiation therapy.

The US holds a significant share of the North America glioma treatment market in North America. The market growth in this country is primarily driven by the increasing prevalence of brain tumor, growing technological advancements in glioma treatment, and the rising number of smokers. According to the American Society of Clinical Oncology (ASCO), in 2022, nearly 24,530 adults (13,840 men and 10,690 women) are estimated to be diagnosed with primary cancerous tumors of the brain and spinal cord in the US. Brain tumors are the primary central nervous system (CNS) malignancies, which account for 85-90% of all primary CNS cases. The demand for faster treatment is growing with the rising number of brain tumor cases. According to the Brain Tumor Registry of Canada, 4 out of 100,000 people in Canada suffer from glioblastoma, and nearly 1,000 Canadians are diagnosed with glioblastoma each year. The glioblastoma treatment market players are adopting various organic and inorganic strategies to succeed in the Canadian market. In February 2021, Medexus Pharmaceuticals Inc. initiated the commercial launch of Gleolan in Canada, which was previously only distributed under the Health Canada special access program. Gleolan is an imaging agent that causes high-grade gliomas (malignant and rapidly progressing brain tumors) to fluoresce under blue light, helping neurosurgeons better visualize these gliomas for complete removal. There are currently no other approved optical imaging agents in Canada for visualizing malignant tissues during glioma surgery. Further, developing healthcare infrastructure, increasing investments in research & development, and improvements in treatment procedures are anticipated to drive the North America glioma treatment market in Mexico during the forecast period.

North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Glioma Treatment Market Segmentation

The North America glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the North America glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the North America glioma treatment market in 2022.

Based on treatment type, the North America glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the North America glioma treatment market in 2022.

Based on grade, the North America glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the North America glioma treatment market in 2022.

Based on end user, the North America glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the North America glioma treatment market in 2022.

Based on country, the North America glioma treatment market is segmented into Germany, the US, Canada, and Mexico. The US dominated the North America glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the North America glioma treatment market.

Product Code: BMIRE00029270

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Glioma Treatment Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Initiatives by Regional and State Governments to Provide Patients Access to Treatment
- 4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
- 4.3.1 Advancements in Healthcare Sector
4.4 Future Trends
- 4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:

5. Glioma Treatment Market - North America Market Analysis

5.1 North America Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

6.1 Overview
6.2 North America Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
- 6.3.1 Overview
- 6.3.2 Astrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
- 6.4.1 Overview
- 6.4.2 Oligoastrocytoma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
- 6.5.1 Overview
- 6.5.2 Oligodendroglioma: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

7.1 Overview
7.2 North America Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
- 7.3.1 Overview
- 7.3.2 Surgery: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
- 7.4.1 Overview
- 7.4.2 Chemotherapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
- 7.5.1 Overview
- 7.5.2 Radiation Therapy: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

8.1 Overview
8.2 North America Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
- 8.3.1 Overview
- 8.3.2 Low Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 Grade I: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Grade II: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
- 8.4.1 Overview
- 8.4.2 High Grade: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.1 Grade III: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.2 Grade IV: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 North America Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
- 9.3.1 Overview
- 9.3.2 Hospital & Clinics: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: North America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Glioma Treatment Market - Country Analysis

10.1 Overview
- 10.1.1 North America Glioma Treatment Market, by Country
  - 10.1.1.1 US
    - 10.1.1.1.1 US: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.1.2 US: North America Glioma Treatment Market, by Disease
    - 10.1.1.1.3 US: North America Glioma Treatment Market, by Treatment Type
    - 10.1.1.1.4 US: North America Glioma Treatment Market, by Grade
    - 10.1.1.1.4.1 US: North America Glioma Treatment Market, by Low Grade
    - 10.1.1.1.4.2 US: North America Glioma Treatment Market, by High Grade
    - 10.1.1.1.5 US: North America Glioma Treatment Market, by End User
  - 10.1.1.2 Canada
    - 10.1.1.2.1 Canada: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.2.2 Canada: North America Glioma Treatment Market, by Disease
    - 10.1.1.2.3 Canada: North America Glioma Treatment Market, by Treatment Type
    - 10.1.1.2.4 Canada: North America Glioma Treatment Market, by Grade
    - 10.1.1.2.4.1 Canada: North America Glioma Treatment Market, by Low Grade
    - 10.1.1.2.4.2 Canada: North America Glioma Treatment Market, by High Grade
    - 10.1.1.2.5 Canada: North America Glioma Treatment Market, by End User
  - 10.1.1.3 Mexico
    - 10.1.1.3.1 Mexico: North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.3.2 Mexico: North America Glioma Treatment Market, by Disease
    - 10.1.1.3.3 Mexico: North America Glioma Treatment Market, by Treatment Type
    - 10.1.1.3.4 Mexico: North America Glioma Treatment Market, by Grade
    - 10.1.1.3.4.1 Mexico: North America Glioma Treatment Market, by Low Grade
    - 10.1.1.3.4.2 Mexico: North America Glioma Treatment Market, by High Grade
    - 10.1.1.3.5 Mexico: North America Glioma Treatment Market, by End User

11. North America Glioma Treatment Market Industry Landscape

11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
- 11.3.1 Overview
11.4 Inorganic Developments
- 11.4.1 Overview

12. Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Arbor Pharmaceuticals LLC
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Merck & Co Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Sun Pharmaceutical Industries Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Amgen Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Teva Pharmaceutical Industries Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Pfizer Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Amneal Pharmaceuticals Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Karyopharm Therapeutics Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Biocon Ltd
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms